Crizalk 250mg

Crizotinib is a drug, intended for the treatment of non-small cell lung cancer with a manifestation of phosphotransferase of malignant lymphoma. About 5 % of cancer patients are diagnosed with this gene mutation. It leads to the replication and increase of all cancer cells.

Crizalk 250mg is an oral drug that inhibits the growth of malignant lymphomas. Crizotinib destroys the composite protein, which results in the blocking of cellular signaling (and thereby promotes the development of tumors). Therefore, the change of composite protein is important for the process of development of malignant tumors (usually neurobloastoma). Moreover, Crizotinib blocks the replication of carcinogens. Carcinogens are another factor that promotes the development of malignant tumors. The use of Crizalk 250mg stops the development of tumors or destroys them completely. Crizotinib reduces and stabilizes the size of tumor in almost 92% of patients. Crizotinib affects the cancer cells by changing and stopping their growth and by introducing into the cancer cells.

Today, target therapy is used to fight the non-small cell carcinoma. Its purpose is to destroy certain cancer cells without affecting the normal ones. In this case, ALK protein, present in the cancer cells, becomes the target.
Crizalk is intended for the treatment of patients suffering from locally advanced or metastatic form of non-small cancer cells with pathology of anaplastic lymphoma kinase gene.

Capsules of Crizalk 250mg should be taken twice a day.
The capsules must be taken with large quantities of liquid. The dose is defined and corrected by the doctor.

Safety and effectiveness of Crizalk 250mg was evaluated during the non-comparative study involving 50 patients with ROS-1-positive metastatic NSCLC. The participants took Crizalk 250mg twice a day each day. The results showed that in 66 % of participants, the tumor reduced significantly or disappeared completely, and this effect lasted for more than 1.5 years (on average).